ESMO Immuno-Oncology 2022 | Key cellular therapy updates in melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, provides an overview of current immunotherapy advances in the field of melanoma. Tumor-infiltrating lymphocytes (TILs) are a promising strategy, especially in patients with PD-1-resistant melanoma. Dr Hamid additionally highlights a novel bi-specific T-cell engager (BiTE) similar to tebentafusp, novel triplet immunotherapy regiments, as well as CAR-T and natural killer (NK) cell therapies. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.